Qiagen Completes Exiqon Tender Offer
News Jun 24, 2016
QIAGEN has announced the successful completion of the conditional, voluntary public tender offer for the shares in Exiqon A/S, a world leader in RNA technology.
QIAGEN N.V. has in total received acceptances from shareholders in Exiqon A/S representing 34,852,938 shares or approximately 94.52% of the share capital and voting rights in Exiqon A/S. The Offer will be settled in cash through the shareholders in Exiqon's own custodian banks and will be effected as soon as possible, but not later than 28 June 2016. QIAGEN N.V. will apply for a delisting of the shares of Exiqon A/S and intends to initiate a squeeze-out of the remaining minority shareholders immediately after completion of the offer.
"We are very pleased to have completed this transaction and will now initiate the integration process", commented Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. "We welcome our new employees to the QIAGEN family and look forward to providing the exciting benefits of the now combined portfolio to research and diagnostic laboratories."
Exiqon has a strong position in the promising new market of non-coding RNA (ncRNA). The company has developed and successfully commercialized comprehensive RNA technology solutions that fit seamlessly into QIAGEN’s Sample to Insight portfolio. Together with Exiqon, QIAGEN expects to deliver a broad and industry leading offering of molecular biology solutions – spanning sample technologies, assay technologies, and bioinformatics.
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.
Comments | 0 ADD COMMENT
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018